SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. will be presenting at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference April 4, 2006 at 2:45 p.m. Eastern Time. Michael Grey, president and chief executive officer of SGX Pharmaceuticals, will provide a corporate overview including the company's lead drug development candidate, Troxatyl(TM), currently in a pivotal phase II/III trial for the treatment of third-line acute myelogenous leukemia, and highlights of the company's strategic collaboration with Novartis to develop BCR-ABL inhibitors for the treatment of drug resistant chronic myelogenous leukemia. CIBC World Markets will host its Annual Biotechnology and Specialty Pharmaceuticals Conference April 4-5 at New York's Millennium Broadway Hotel.
The live presentation will be webcast at: http://www.veracast.com/webcasts/cibcwm/biotech06/15112263.cfm
A recording will be made available for 90 days following the event. The audio webcast will be accessible through the Investors page of the Company's website found at: http://www.sgxpharma.com.
About SGX Pharmaceuticals
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The Company's lead product candidate, Troxatyl(TM), is currently being evaluated in a pivotal phase II/III trial for the treatment of third-line acute myelogenous leukemia, an indication for which there is currently no approved therapy or standard of care. SGX has developed a pipeline of oncology drug candidates based on its enabling, proprietary FAST(TM) drug discovery platform, including a portfolio of next generation BCR-ABL inhibitors. FAST allows for the rapid identification of novel, potent and selective small molecule compounds for well validated but challenging targets. More information on SGX's pipeline and drug discovery platform can be found at www.sgxpharma.com.
Forward-looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to SGX's research and drug discovery and development programs, SGX's collaborations and its drug discovery technology. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements. For a discussion of these risks and uncertainties, please refer to the risk factors section of the final prospectus from SGX's initial public offering filed with the United States Securities and Exchange Commission on February 1, 2006 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Contact: Todd Myers SGX Pharmaceuticals, Inc. (858) 228-1565 tmyers@sgxpharma.com
SGX Pharmaceuticals, Inc.CONTACT: Todd Myers of SGX Pharmaceuticals, Inc., +1-858-228-1565,tmyers@sgxpharma.com
